Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care
- DOI
- 10.1038/s41598-023-44841-w
- Published
- 2023-10-18
- Container
- Scientific Reports
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41598-023-44841-w,
title = {Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care},
author = {Myriam Riek and Almut Scherer and Burkhard Möller and Adrian Ciurea and Ines von Mühlenen and Cem Gabay and Diego Kyburz and Laure Brulhart and Johannes von Kempis and Ruediger B. Mueller and Paul Hasler and Tanja Strahm and Sabine von Känel and Pascal Zufferey and Jean Dudler and Axel Finckh},
year = {2023},
journal = {Scientific Reports},
doi = {10.1038/s41598-023-44841-w},
url = {https://doi.org/10.1038/s41598-023-44841-w}
}RIS
TY - JOUR TI - Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care AU - Myriam Riek AU - Almut Scherer AU - Burkhard Möller AU - Adrian Ciurea AU - Ines von Mühlenen AU - Cem Gabay AU - Diego Kyburz AU - Laure Brulhart AU - Johannes von Kempis AU - Ruediger B. Mueller AU - Paul Hasler AU - Tanja Strahm AU - Sabine von Känel AU - Pascal Zufferey AU - Jean Dudler AU - Axel Finckh PY - 2023 JO - Scientific Reports DO - 10.1038/s41598-023-44841-w UR - https://doi.org/10.1038/s41598-023-44841-w ER -
APA
Riek, M., Scherer, A., Möller, B., Ciurea, A., Mühlenen, I. V., Gabay, C., Kyburz, D., Brulhart, L., Kempis, J. V., Mueller, R. B., Hasler, P., Strahm, T., Känel, S. V., Zufferey, P., Dudler, J., & Finckh, A. (2023). Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Scientific Reports. https://doi.org/10.1038/s41598-023-44841-w
Source records
- crossref · retrieved 2026-09-26T02:45:50.530Z